CD8A and neoplasm: Surprisingly, circulating antiviral CD8+ T cells were unaffected by checkpoint inhibition in all three tumor models (Supplementary Fig. 7b,c,g,h,l,m) but the ratio of antitumor to antiviral CD8+ T cells in circulation was not greatly enhanced by combining checkpoint blockade antibodies with KVK vaccination (Supplementary fig 7d, i, n).